Search clinical trials for: Previous untreated

Total 4348 results

Memorial Sloan Kettering Cancer Center
Yale University; Dana-Farber Cancer Institute

Active, not recruiting

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Leukemia | Leukemia, Hairy Cell | Hairy Cell Leukemia

United States
Pierre Fabre Medicament
Pfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd

Completed

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)

BRAF V600E-mutant Metastatic Colorectal Cancer

France, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
Roswell Park Cancer Institute
GlaxoSmithKline

Active, not recruiting

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
ADC Therapeutics S.A.

Completed

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Puerto Rico
AbbVie

Completed

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Medulloblastoma | Anaplastic Medulloblastoma

United States, Canada, Puerto Rico, Australia, Netherlands
Novartis Pharmaceuticals

Completed

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, Spain, Taiwan, Germany, Netherlands, Singapore, Austria, Japan, Australia, France, Russian Federation, Sweden, Thailand, Korea, Republic of, Lebanon, Norway, United Kingdom, China, India, Brazil, Turkey, Poland, Denmark, Greece, ... and more
Cancer Insight, LLC
Bristol-Myers Squibb; Cancer Research Institute, New York City; Akamis Bio

Active, not recruiting

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION)

Metastatic Pancreatic Adenocarcinoma

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Exelixis

Active, not recruiting

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)

Renal Cell Carcinoma

United States, Japan, Brazil, Argentina, Australia, Chile, Czechia, Germany, Greece, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Spain, Turkey, United Kingdom
Kerry Rogers

Active, not recruiting

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Amyloidosis | Plasma Cell Myeloma

United States
Dana-Farber Cancer Institute
Pharmacyclics LLC.; The Leukemia and Lymphoma Society; Blood Cancer Research...

Active, not recruiting

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR)

Leukemia | Chronic Lymphocytic Leukemia

United States
University Hospital Muenster
Bayer

Active, not recruiting

Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP)

Diffuse Large B Cell Lymphoma

Germany
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

HR-positive, HER2-negative Breast Neoplasms

China
Shanghai Institute Of Biological Products

Completed

A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

Diffuse Large B-Cell Lymphoma

China
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Pfizer

Completed

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Spain, Canada, Austria, Czechia, France, Hungary, Italy, Japan, Mexico, Poland, United Kingdom
University Health Network, Toronto

Active, not recruiting

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

Canada
European Organisation for Research and Treatment...

Completed

Empirical Versus Preemptive Antifungal Therapy

Myelodysplastic Syndromes | Leukemia | Fungal Infection

Belgium, Netherlands, Germany, France, Czechia, Slovakia
University of California, San Diego
Pharmacyclics LLC.

Active, not recruiting

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Chronic Lymphocytic Leukemia

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma | Neurotoxicity | Therapy-related Toxicity

United States, Canada
National Heart, Lung, and Blood Institute (NHLBI)
GlaxoSmithKline; University of Virginia

Completed

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Small Lymphocytic Lymphoma | CLL (Chronic Lymphocytic Leukemia)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States, Israel, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Spain, Sweden, Ta... and more
BeiGene

Active, not recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, China, Taiwan, Belgium, France, United Kingdom, Spain, New Zealand, Australia, Czechia, Italy, Poland, Russian Federation, Sweden, Austria
Sumitomo Pharma America, Inc.

Terminated

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Myelodysplastic Syndromes (MDS)

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Triple Negative Breast Cancer (TNBC)
Dana-Farber Cancer Institute

Active, not recruiting

Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma

Follicular Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Sarcoma

United States
Immutep S.A.S.
Merck Sharp & Dohme LLC

Active, not recruiting

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)

NSCLC | HNSCC

Spain, United States, United Kingdom, Australia, Ukraine
University of Nebraska
National Cancer Institute (NCI)

Completed

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Secondary Myelofibrosis

United States
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

Primary Mediastinal B-cell Lymphoma

Norway, United Kingdom, Italy, Switzerland, Czechia, United States, China, Argentina, Canada, Germany, Poland, Portugal, Sweden, Ukraine
GlaxoSmithKline

Active, not recruiting

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Neoplasms

United States, Netherlands, Canada, United Kingdom
Jazz Pharmaceuticals

Completed

A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia (V-FAST)

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Untreated Adult Acute Myeloid Leukemia

United States
Hoffmann-La Roche

Completed

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Dana-Farber Cancer Institute
Secura Bio, Inc.

Active, not recruiting

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Chronic Lymphocytic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Untreated Childhood Medulloblastoma

United States, Canada, Australia, New Zealand, Switzerland, Netherlands
National Cancer Institute (NCI)

Completed

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

Malignant Solid Neoplasm | Extensive Stage Lung Small Cell Carcinoma | Metastatic Malignant Neoplasm in the Brain

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Chordoma | Rhabdomyosarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Untreated Childhood Rhabdomyosarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 and other conditions

United States, Netherlands, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Amgen

Withdrawn

Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy

Severe Aplastic Anemia (SAA)
SecuraBio

Terminated

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

CD20+ Follicular Lymphoma

Belgium, Italy, United States, Spain, United Kingdom, France
University of Alabama at Birmingham

Terminated

Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) (CHOP U2)

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen, LP

Completed

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

CD20 Positive | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Completed

Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma

Indolent Non-Hodgkin's Lymphoma

United States
Jules Bordet Institute
AstraZeneca

Active, not recruiting

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC (SYNERGY)

Triple Negative Breast Cancer

France, Belgium
Sumithira Vasu

Completed

Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

Hemophilia A

Spain, United States, Denmark, Italy, Taiwan, Malaysia, Belgium, Thailand, Turkey, Austria, Bulgaria, Canada, Finland, France, Germany, Hong Kong, Hungary, Korea, Republic of, Netherlands, Norway, Singapore, Ukraine, United Kingdom
University of Nebraska
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Lymphoma

United States

Search clinical trials for: Previous untreated

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations